Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes late last week released new data on its Attune knee system from a study and internal report, touting potential benefits of the system.
The company released data from a study of the Attune knee implant comparing it to preoperative baseline at six months. Data from the study indicated a statistically significant improvement in knee function for patients with the Attune knee as measured by the Knee injury and Osteoarthritis Outcome Score-Physical Function Short Form.
Results were presented at the 2nd World Arthroplasty congress in Rome, the company said.
The study examined 200 cases from The Netherlands, and determined that in 80% of those cases improvements on the KOOS-PS scale were realized within six months, with statistically significant improvements observed at intervals prior to six months. Pain and other patient reported outcome measures were also statistically significantly better at six months when compared to pre-operative baselines.
DePuy Synthes also released data from an internally generated report summarizing a series of studies across a number of countries with differing healthcare systems, touting a reduced length of stay for Attune patients.
The retrospective review looked to examine the connection between implant design and patient hospital length of stay, and took data from five real-world evidence studies conducted by the company to evaluate whether patients with the Attune knee had shorter LOS versus comparative implants.
The report concluded that in each of the evaluated studies, patients receiving the Attune knee were discharged sooner than with comparative implants. Evidence indicated that the Attune knee could facilitate earlier hospital discharge, with an observed reduced length of between 0.19 and 4 days on average, DePuy Synthes said.
“I’m delighted that this data demonstrated that study patients receiving the Attune Knee experienced positive outcomes related to the rate of return of functional outcomes and reduced length of stay, allowing these patients to get back to a positive quality of life,” EMEA joint reconstruction VP Torbjorn Skold said in a prepared release.
“This multi-center outcomes study is further evidence of the positive performance of the Attune Knee, and this study provides additional evidence on the rate of recovery – information that is useful when counseling patients before surgery. From my intraoperative and patient follow up experiences, the Attune Knee appears to provide greater stability than other implants I have used, which may be a contributing factor to these positive results. While it’s important to acknowledge that many factors can contribute to differences in length of stay, the data seems to suggest that implant design may be an important factor to consider in total knee arthroplasty procedures. This latest evidence gives me greater confidence that the device could help hospitals cost-effectively keep pace with the growing total knee arthroplasty demand,” Dr. Geert Meermans of The Netherlands’ Bravis Hospital said in a press release.
This week, DePuy Synthes said it inked a deal to acquire the assets of Medical Enterprises Distribution, including its automated ME1000 surgical impactor designed for hip replacements, for an undisclosed amount.
